aluminum sulfate has been researched along with c-peptide in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Casas, R; Chéramy, M; Hampe, CS; Johansson, I; Ludvigsson, J; Skoglund, C | 1 |
| Akerman, L; Axelsson, S; Casas, R; Chéramy, M; Ludvigsson, J; Pihl, M | 1 |
| Achenbach, P; Agardh, CD; Bonifacio, E; Furmaniak, J; Hansen, JM; Hausmann, S; Krause, S; Landherr, U; Lernmark, A; Link, K; Lynch, KF; Powell, M; Rees-Smith, B; Ziegler, AG | 1 |
| Åkerman, L; Axelsson, S; Casas, R; Cheramy, M; Ludvigsson, J; Tavira, B | 1 |
| Achenbach, P; Barcenilla, H; Casas, R; Dietrich, F; Ludvigsson, J; Puente-Marin, S; Tavira, B; Wahlberg, J | 1 |
| Hannelius, U; Ludvigsson, J; Nowak, C | 1 |
| Casas, R; Clemente-León, M; Dietrich, F; Ferrer Lozano, M; Gómez-Gila, A; Hanas, R; Hannelius, U; Hernandez, C; Lind, M; Ludvigsson, J; Lundberg, E; Martínez-Brocca, MA; Nattero-Chavez, L; Nowak, C; Pelikanova, T; Pruhova, S; Puente-Marin, S; Rica, I; Ruiz de Adana, M; Sas, T; Sumnik, Z; Wahlberg, J | 1 |
| Bruggeman, Y; Ellis, D; Gysemans, C; Laureys, J; Martens, PJ; Mathieu, C; Teyton, L; Viaene, M | 1 |
| Achenbach, P; Barcenilla, H; Casas, R; Dietrich, F; Ludvigsson, J; Puente-Marin, S | 1 |
1 review(s) available for aluminum sulfate and c-peptide
| Article | Year |
|---|---|
Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of glutamic acid decarboxylase (GAD)-alum immunotherapy in recent-onset type 1 diabetes.
Topics: Alum Compounds; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Immunologic Factors; Immunotherapy | 2022 |
7 trial(s) available for aluminum sulfate and c-peptide
| Article | Year |
|---|---|
GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
Topics: Adjuvants, Immunologic; Adolescent; Alum Compounds; Antibodies; Area Under Curve; Autoantibodies; Biocatalysis; C-Peptide; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Glutamate Decarboxylase; Humans; Immune Sera; Immunity, Humoral; Immunoglobulin E; Immunoglobulin G; Immunotherapy, Active; Tetanus Toxoid; Treatment Outcome | 2010 |
GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
Topics: Adolescent; Alum Compounds; Autoantibodies; C-Peptide; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Injections, Subcutaneous; Insulin; Insulin Secretion; Male; Young Adult | 2014 |
GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.
Topics: Adult; Aged; Alum Compounds; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Disease Progression; Double-Blind Method; Female; Glucose Intolerance; Glutamate Decarboxylase; Humans; Insulin-Secreting Cells; Male; Middle Aged; Vaccination; Vaccines, Synthetic | 2014 |
Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD
Topics: Adolescent; Alum Compounds; Autoantibodies; C-Peptide; Child; Cytokines; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Finland; Glutamate Decarboxylase; Hemagglutinins; Humans; Immune System; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Insulin; Insulin Secretion; Male; Normal Distribution; Sweden; Time Factors; Vaccination; Young Adult | 2017 |
Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial).
Topics: Alum Compounds; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Follow-Up Studies; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Immunoglobulin G | 2022 |
Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
Topics: Adolescent; Alum Compounds; Blood Glucose; Blood Glucose Self-Monitoring; C-Peptide; Child; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Glycemic Control; HLA-DR3 Antigen; Humans; Vitamin D; Young Adult | 2022 |
Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Topics: C-Peptide; Cytokines; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Haplotypes; HLA Antigens; Humans; Immunity, Cellular; Interleukin-10; Interleukin-13; Interleukin-5 | 2023 |
1 other study(ies) available for aluminum sulfate and c-peptide
| Article | Year |
|---|---|
Preventing type 1 diabetes in late-stage pre-diabetic NOD mice with insulin: A central role for alum as adjuvant.
Topics: Animals; C-Peptide; CD8-Positive T-Lymphocytes; Diabetes Mellitus, Type 1; Female; Forkhead Transcription Factors; Humans; Infant, Newborn; Insulin; Mice; Mice, Inbred NOD; Mice, Obese; Peptides; Prediabetic State | 2022 |